Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. commercializes cash-pay medical aesthetic products for the global performance beauty market. Its portfolio centers on Jeuveau® (prabotulinumtoxinA-xvfs), known as Nuceiva® outside the United States, and injectable hyaluronic acid gel collections marketed under the Evolysse® and Estyme® brands.
Recurring Evolus news includes quarterly financial results, revenue outlooks, product and market expansion for injectable aesthetics, CE Mark certification for HA gel collections, national-account and customer engagement updates, healthcare conference participation, and equity compensation grants under Nasdaq inducement rules. Company updates also discuss operations across the United States, Canada, Europe, and Australia.
Summary not available.
Evolus, a performance beauty company, announced participation in the H.C. Wainwright Global Investment Conference on May 24, 2022, from 9:00-9:30 am ET. The event aims to showcase Evolus's cutting-edge products, particularly Jeuveau®, a neurotoxin dedicated to aesthetics and FDA-approved in 2019. An audio webcast will be available on their website, with a replay for 90 days post-event. Evolus is committed to customer-centric innovation in the aesthetic market.
Evolus, Inc. (NASDAQ: EOLS) reported Q1 2022 net revenue of $33.9 million, a 177% increase from Q1 2021. The company now expects full-year revenue between $143 and $150 million, reflecting a nearly 50% year-over-year growth. Operating expenses rose to $49.4 million due to enhanced investments, while cash and equivalents stood at $106.7 million. Despite a $15.4 million operational loss, the company maintains a solid cash position to support its growth strategy and plans to launch Nuceiva® in Europe in Q3 2022.
Evolus, Inc. (NASDAQ: EOLS) will announce its first quarter 2022 financial results on May 10, 2022, after U.S. market close. Following the release, management will host a conference call at 4:30 p.m. ET for discussion, followed by a Q&A session. Investors can join via phone at (877) 407-6184 (U.S.) or (201) 389-0877 (international), or through a live webcast on the Evolus website. A replay of the call will be available afterward. Evolus focuses on customer-centric breakthrough products in the aesthetics market, with Jeuveau® as its flagship neurotoxin.
Evolus, Inc. (NASDAQ: EOLS) has enrolled its first patient in a pivotal clinical study assessing an ‘extra-strength’ dose of Jeuveau® (prabotulinumtoxinA-xvfs), designed for aesthetic use. This multicenter, double-blind trial will involve 150 patients and compare the efficacy of 40 units of Jeuveau® against the standard 20-unit doses of Jeuveau® and BOTOX® Cosmetic. The company anticipates study completion in the first half of 2023, aiming to address a need in the aesthetic market, as clinicians have expressed interest in a stronger dosage option.
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, will participate in the Barclays Global Healthcare Conference on March 15, 2022, from 1:35-2:00 p.m. ET. The event emphasizes Evolus’ commitment to delivering innovative products, including their FDA-approved neurotoxin, Jeuveau®, which focuses on aesthetic applications. The presentation will be accessible via an audio webcast on Evolus’ investor relations website, with a replay available for 90 days post-event.
Evolus, Inc. (NASDAQ: EOLS) announces the retirement of Chief Financial Officer Lauren Silvernail, effective May 31, 2022, after nearly four years with the company. During her tenure, she significantly contributed to the company's growth, leading efforts in commercial infrastructure and balance sheet restructuring. Silvernail also negotiated a $125 million credit facility to support the company through cash flow breakeven, positioning Evolus for future success. The search for her successor is already underway.
Evolus reported Q4 2021 net revenue of $34.7 million, a 68% increase year-over-year. Full-year 2021 revenue reached $99.7 million, up 76% from 2020. The company reaffirmed guidance for 2022 revenues between $143 million and $150 million, projecting growth of 43% to 50%. Evolus added 400 new customer accounts in Q4 and achieved significant marketing successes, including over 1 billion impressions. Despite losses from operations reducing by 83%, the company is on track for growth, aiming for better profit margins post-settlement royalty reductions in September 2022.
Evolus, Inc. (NASDAQ: EOLS) announced the appointment of Christos Monovoukas as Senior Vice President of Corporate Development, effective February 28, 2022. Monovoukas has over 20 years of experience in business development, previously serving at Olympus Corporation and Smith & Nephew. In connection with his hiring, Evolus granted him inducement awards consisting of options for 171,103 shares and 39,012 RSUs, with an exercise price of $9.15. CEO David Moatazedi expressed confidence in Monovoukas' ability to support the company's growth strategy.
Evolus, Inc. (NASDAQ: EOLS) announced it will report its fourth quarter and year-end 2021 financial results on March 3, 2022, after U.S. market close. A conference call and live webcast will follow at 4:30 p.m. ET, including a Q&A session. Participants can join via phone or through the Evolus website. A replay of the call will be available after completion. Evolus, known for its neurotoxin Jeuveau®, focuses on redefining the aesthetic market with innovative customer-centric products.